Immune-based Therapies for Non-small Cell Lung Cancer.
Lung cancer is the leading cause of cancer-related death worldwide. Treatment of non-small cell lung cancer has evolved tremendously over the past decade. Specifically, immune checkpoint inhibitors have become an increasingly interesting target of pharmacological blockade. These immune inhibitors have shown promising results in front-line therapy and after failure of multiple lines, as well as in monotherapy and combination with other therapies. Vaccination in non-small cell lung cancer is also an emerging field of research that holds promising results for the future of immunotherapy in non-small cell lung cancer. This review presents a concise update on the most recent data regarding the role of checkpoint inhibitors as well as vaccination in non-small cell lung cancer.
Department of Internal Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, U.S.A.
Hind
H
Rafei
Clearview Cancer Institute, Huntsville, AL, U.S.A.
Ehab
E
El-Bahesh
Keserwan Medical Center, Jounieh, Lebanon.
Antoine
A
Finianos
Department of Internal Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, U.S.A.
Samah
S
Nassereddine
Division of Hematology/Oncology and GW Cancer Center, George Washington University Medical Faculty Associates, Washington, DC, U.S.A. itabbara@mfa.gwu.edu.
Imad
I
Tabbara
D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D008175:Lung Neoplasms / Q000276:immunology / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic
Non-small cell lung cancer; checkpoint inhibitors; immunotherapy; review; vaccine